An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies

Enhancing Radiologist Productivity with Artificial Intelligence in Magnetic Resonance Imaging (MRI): A Narrative Review

Artificial intelligence (AI) shows promise in streamlining MRI workflows by reducing radiologists' workload and improving diagnostic accuracy. Despite MRI's extensive clinical use, systematic evaluation of AI-driven productivity gains in MRI remains limited. This review addresses that gap by synthesizing evidence on how AI can shorten scanning and reading times, optimize worklist triage, and automate segmentation. On 15 November 2024, we searched PubMed, EMBASE, MEDLINE, Web of Science, Google Scholar, and Cochrane Library for English-language studies published between 2000 and 15 November 2024, focusing on AI applications in MRI. Additional searches of grey literature were conducted. After screening for relevance and full-text review, 67 studies met inclusion criteria. Extracted data included study design, AI techniques, and productivity-related outcomes such as time savings and diagnostic accuracy. The included studies were categorized into five themes: reducing scan times, automating segmentation, optimizing workflow, decreasing reading times, and general time-saving or workload reduction. Convolutional neural networks (CNNs), especially architectures like ResNet and U-Net, were commonly used for tasks ranging from segmentation to automated reporting. A few studies also explored machine learning-based automation software and, more recently, large language models. Although most demonstrated gains in efficiency and accuracy, limited external validation and dataset heterogeneity could reduce broader adoption. AI applications in MRI offer potential to enhance radiologist productivity, mainly through accelerated scans, automated segmentation, and streamlined workflows. Further research, including prospective validation and standardized metrics, is needed to enable safe, efficient, and equitable deployment of AI tools in clinical MRI practice.

Intra- and peri-tumoral radiomics based on dynamic contrast-enhanced MRI for prediction of benign disease in BI-RADS 4 breast lesions: a multicentre study

BACKGROUND AND PURPOSE

The study aimed to create a radiomics model based on breast intra- and peri-tumoral regions in dynamic contrast-enhanced (DCE) MRI to distinguish benign from malignant breast lesions of Breast Imaging Reporting and Data System (BI-RADS) 4.

MATERIALS AND METHODS

A total of 516 patients from Hospital 1 were assigned to the training cohort. Then, 146 and 52 patients were enrolled from Hospital 2 and 3, respectively, as the internal and external test cohort. Seven classification models were built, using features extracted from the intra- and peri-tumoral regions. Diagnostic performance was evaluated by receiver operating characteristics (ROC) analysis and compared by the DeLong test. Subgroup analysis was performed after stratifying all lesions by enhancement pattern and the subdivision of BI-RADS 4.

RESULTS

The Comb2 model, built with features from peri-tumoral 2 mm and intra-tumoral region, demonstrated the best performance with AUCs of 0.828 and 0.844 in the internal and external test cohort, respectively. The Comb2 model was robust in both mass and non-mass enhancement (NME) lesions. At the three exploratory cutoff values on the ROC curve, the model identified 9.1% (sensitivity of C1 ≥ 98%), 27.3% (sensitivity of C2 ≥ 95%) and 36.4% (sensitivity of C3 ≥ 90%) of the benign lesions in the external test cohort. Applying the identified cutoff values in the external test cohort showed the potential to lower the number of unnecessary biopsies of benign lesions.

CONCLUSION

An MRI-based radiomics model built with features extracted from the intra-tumoral region combined with the peri-tumoral 2 mm showed the best potential to reduce false-positive diagnoses and may avoid unnecessary biopsies with a low underestimate risk.

An updated overview of radiomics-based artificial intelligence (AI) methods in breast cancer screening and diagnosis

Current imaging methods for diagnosing breast cancer (BC) are associated with limited sensitivity and specificity and modest positive predictive power. The recent progress in image analysis using artificial intelligence (AI) has created great promise to improve BC diagnosis and subtype differentiation. In this case, novel quantitative computational methods, such as radiomics, have been developed to enhance the sensitivity and specificity of early BC diagnosis and classification. The potential of radiomics in improving the diagnostic efficacy of imaging studies has been shown in several studies. In this review article, we discuss the radiomics workflow and current handcrafted radiomics methods in the diagnosis and classification of BC based on the most recent studies on different imaging modalities, e.g., MRI, mammography, contrast-enhanced spectral mammography (CESM), ultrasound imaging, and digital breast tumosynthesis (DBT). We also discuss current challenges and potential strategies to improve the specificity and sensitivity of radiomics in breast cancer to help achieve a higher level of BC classification and diagnosis in the clinical setting. The growing field of AI incorporation with imaging information has opened a great opportunity to provide a higher level of care for BC patients.

Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives

Radiomics, analysing quantitative features from medical imaging, has rapidly become an emerging field in translational oncology. Radiomics has been investigated in several neoplastic malignancies as it might allow for a non-invasive tumour characterization and for the identification of predictive and prognostic biomarkers. Over the last few years, evidence has been accumulating regarding potential clinical applications of machine learning in many crucial moments of cancer patients' history. However, the incorporation of radiomics in clinical decision-making process is still limited by low data reproducibility and study variability. Moreover, the need for prospective validations and standardizations is emerging. In this narrative review, we summarize current evidence regarding radiomic applications in high-incidence cancers (breast and lung) for screening, diagnosis, staging, treatment choice, response, and clinical outcome evaluation. We also discuss pro and cons of the radiomic approach, suggesting possible solutions to critical issues which might invalidate radiomics studies and propose future perspectives.

Artificial intelligence-based, semi-automated segmentation for the extraction of ultrasound-derived radiomics features in breast cancer: a prospective multicenter study

PURPOSE

To investigate the feasibility of an artificial intelligence (AI)-based semi-automated segmentation for the extraction of ultrasound (US)-derived radiomics features in the characterization of focal breast lesions (FBLs).

MATERIAL AND METHODS

Two expert radiologists classified according to US BI-RADS criteria 352 FBLs detected in 352 patients (237 at Center A and 115 at Center B). An AI-based semi-automated segmentation was used to build a machine learning (ML) model on the basis of B-mode US of 237 images (center A) and then validated on an external cohort of B-mode US images of 115 patients (Center B).

RESULTS

A total of 202 of 352 (57.4%) FBLs were benign, and 150 of 352 (42.6%) were malignant. The AI-based semi-automated segmentation achieved a success rate of 95.7% for one reviewer and 96% for the other, without significant difference (p = 0.839). A total of 15 (4.3%) and 14 (4%) of 352 semi-automated segmentations were not accepted due to posterior acoustic shadowing at B-Mode US and 13 and 10 of them corresponded to malignant lesions, respectively. In the validation cohort, the characterization made by the expert radiologist yielded values of sensitivity, specificity, PPV and NPV of 0.933, 0.9, 0.857, 0.955, respectively. The ML model obtained values of sensitivity, specificity, PPV and NPV of 0.544, 0.6, 0.416, 0.628, respectively. The combined assessment of radiologists and ML model yielded values of sensitivity, specificity, PPV and NPV of 0.756, 0.928, 0.872, 0.855, respectively.

CONCLUSION

AI-based semi-automated segmentation is feasible, allowing an instantaneous and reproducible extraction of US-derived radiomics features of FBLs. The combination of radiomics and US BI-RADS classification led to a potential decrease of unnecessary biopsy but at the expense of a not negligible increase of potentially missed cancers.

Added value of clinical decision rules for the management of enhancing breast MRI lesions: A systematic comparison of the Kaiser score and the Göttingen score

PURPOSE

We investigated the added value of two internationally used clinical decision rules in the management of enhancing lesions on breast MRI.

METHODS

This retrospective, institutional review board approved study included consecutive patients from two different populations. Patients received breast MRI according to the recommendations of the European Society of Breast Imaging (EUSOBI). Initially, all examinations were assessed by expert readers without using clinical decision rules. All lesions rated as category 4 or 5 according to the Breast Imaging Reporting and Data System were histologically confirmed. These lesions were re-evaluated by an expert reader blinded to the histology. He assigned each lesion a Göttingen score (GS) and a Kaiser score (KS) on different occasions. To provide an estimate on inter-reader agreement, a second fellowship-trained reader assessed a subset of these lesions. Subgroup analyses based on lesion type (mass vs. non-mass), size (>1 cm vs. ≤ 1 cm), menopausal status, and significant background parenchymal enhancement were conducted. The areas under the ROC curves (AUCs) for the GS and KS were compared, and the potential to avoid unnecessary biopsies was determined according to previously established cutoffs (KS > 4, GS > 3) RESULTS: 527 lesions in 506 patients were included (mean age: 51.8 years, inter-quartile-range: 43.0-61.0 years). 131/527 lesions were malignant (24.9 %; 95 %-confidence-interval: 21.3-28.8). In all subgroups, the AUCs of the KS (median = 0.91) were higher than those of the GS (median = 0.83). Except for "premenopausal patients" (p = 0.057), these differences were statistically significant (p ≤ 0.01). Kappa agreement was higher for the KS (0.922) than for the GS (0.358).

CONCLUSION

Both the KS and the GS provided added value for the management of enhancing lesions on breast MRI. The KS was superior to the GS in terms of avoiding unnecessary biopsies and showed superior inter-reader agreement; therefore, it may be regarded as the clinical decision rule of choice.

Artificial intelligence in breast imaging: potentials and challenges

Breast cancer, which is the most common type of malignant tumor among humans, is a leading cause of death in females. Standard treatment strategies, including neoadjuvant chemotherapy, surgery, postoperative chemotherapy, targeted therapy, endocrine therapy, and radiotherapy, are tailored for individual patients. Such personalized therapies have tremendously reduced the threat of breast cancer in females. Furthermore, early imaging screening plays an important role in reducing the treatment cycle and improving breast cancer prognosis. The recent innovative revolution in artificial intelligence (AI) has aided radiologists in the early and accurate diagnosis of breast cancer. In this review, we introduce the necessity of incorporating AI into breast imaging and the applications of AI in mammography, ultrasonography, magnetic resonance imaging, and positron emission tomography/computed tomography based on published articles since 1994. Moreover, the challenges of AI in breast imaging are discussed.

Unsupervised pre-training of graph transformers on patient population graphs

Pre-training has shown success in different areas of machine learning, such as Computer Vision, Natural Language Processing (NLP), and medical imaging. However, it has not been fully explored for clinical data analysis. An immense amount of clinical records are recorded, but still, data and labels can be scarce for data collected in small hospitals or dealing with rare diseases. In such scenarios, pre-training on a larger set of unlabeled clinical data could improve performance. In this paper, we propose novel unsupervised pre-training techniques designed for heterogeneous, multi-modal clinical data for patient outcome prediction inspired by masked language modeling (MLM), by leveraging graph deep learning over population graphs. To this end, we further propose a graph-transformer-based network, designed to handle heterogeneous clinical data. By combining masking-based pre-training with a transformer-based network, we translate the success of masking-based pre-training in other domains to heterogeneous clinical data. We show the benefit of our pre-training method in a self-supervised and a transfer learning setting, utilizing three medical datasets TADPOLE, MIMIC-III, and a Sepsis Prediction Dataset. We find that our proposed pre-training methods help in modeling the data at a patient and population level and improve performance in different fine-tuning tasks on all datasets.

Fully automatic classification of breast lesions on multi-parameter MRI using a radiomics model with minimal number of stable, interpretable features

PURPOSE

To build an automatic computer-aided diagnosis (CAD) pipeline based on multiparametric magnetic resonance imaging (mpMRI) and explore the role of different imaging features in the classification of breast cancer.

MATERIALS AND METHODS

A total of 222 histopathology-confirmed breast lesions, together with their BI-RADS scores, were included in the analysis. The cohort was randomly split into training (159) and test (63) cohorts, and another 50 lesions were collected as an external cohort. An nnUNet-based lesion segmentation model was trained to automatically segment lesion ROI, from which radiomics features were extracted for diffusion-weighted imaging (DWI), T2-weighted imaging (T2WI), and contrast-enhanced (DCE) pharmacokinetic parametric maps. Models based on combinations of sequences were built using support vector machine (SVM) and logistic regression (LR). Also, the performance of these sequence combinations and BI-RADS scores were compared. The Dice coefficient and AUC were calculated  to evaluate the segmentation and classification results. Decision curve analysis (DCA) was used to assess clinical utility.

RESULTS

The segmentation model achieved a Dice coefficient of 0.831 in the test cohort. The radiomics model used only three features from diffusion coefficient (ADC) images, T2WI, and DCE-derived kinetic mapping, and achieved an AUC of 0.946 [0.883-0.990], AUC of 0.842 [0.6856-0.998] in the external cohort, which was higher than the BI-RADS score with an AUC of 0.872 [0.752-0.975]. The joint model using both radiomics score and BI-RADS score achieved the highest test AUC of 0.975 [0.935-1.000], with a sensitivity of 0.920 and a specificity of 0.923.

CONCLUSION

Three radiomics features can be used to construct an automatic radiomics-based pipeline to improve the diagnosis of breast lesions and reduce unnecessary biopsies, especially when using jointly with BI-RADS scores.

Four-Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast-Enhanced MRI

BACKGROUND

Breast cancer response to neoadjuvant chemotherapy (NAC) is typically evaluated through the assessment of tumor size reduction after a few cycles of NAC. In case of treatment ineffectiveness, this results in the patient suffering potentially severe secondary effects without achieving any actual benefit.

PURPOSE

To identify patients achieving pathologic complete response (pCR) after NAC by spatio-temporal radiomic analysis of dynamic contrast-enhanced (DCE) MRI images acquired before treatment.

STUDY TYPE

Single-center, retrospective.

POPULATION

A total of 251 DCE-MRI pretreatment images of breast cancer patients.

FIELD STRENGTH/SEQUENCE

1.5 T/3 T, T1-weighted DCE-MRI.

ASSESSMENT

Tumor and peritumoral regions were segmented, and 348 radiomic features that quantify texture temporal variation, enhancement kinetics heterogeneity, and morphology were extracted. Based on subsets of features identified through forward selection, machine learning (ML) logistic regression models were trained separately with all images and stratifying on cancer molecular subtype and validated with leave-one-out cross-validation.

STATISTICAL TESTS

Feature significance was assessed using the Mann-Whitney U-test. Significance of the area under the receiver operating characteristics (ROC) curve (AUC) of the ML models was assessed using the associated 95% confidence interval (CI). Significance threshold was set to 0.05, adjusted with Bonferroni correction.

RESULTS

Nine features related to texture temporal variation and enhancement kinetics heterogeneity were significant in the discrimination of cases achieving pCR vs. non-pCR. The ML models achieved significant AUC of 0.707 (all cancers, n = 251, 59 pCR), 0.824 (luminal A, n = 107, 14 pCR), 0.823 (luminal B, n = 47, 15 pCR), 0.844 (HER2 enriched, n = 25, 11 pCR), 0.803 (triple negative, n = 72, 19 pCR).

DATA CONCLUSIONS

Differences in imaging phenotypes were found between complete and noncomplete responders. Furthermore, ML models trained per cancer subtype achieved high performance in classifying pCR vs. non-pCR cases. They may, therefore, have potential to help stratify patients according to the level of response predicted before treatment, pending further validation with larger prospective cohorts.

EVIDENCE LEVEL

4 TECHNICAL EFFICACY: Stage 4.

The potential of predictive and prognostic breast MRI (P2-bMRI)

Magnetic resonance imaging (MRI) is an important part of breast cancer diagnosis and multimodal workup. It provides unsurpassed soft tissue contrast to analyse the underlying pathophysiology, and it is adopted for a variety of clinical indications. Predictive and prognostic breast MRI (P2-bMRI) is an emerging application next to these indications. The general objective of P2-bMRI is to provide predictive and/or prognostic biomarkers in order to support personalisation of breast cancer treatment. We believe P2-bMRI has a great clinical potential, thanks to the in vivo examination of the whole tumour and of the surrounding tissue, establishing a link between pathophysiology and response to therapy (prediction) as well as patient outcome (prognostication). The tools used for P2-bMRI cover a wide spectrum: standard and advanced multiparametric pulse sequences; structured reporting criteria (for instance BI-RADS descriptors); artificial intelligence methods, including machine learning (with emphasis on radiomics data analysis); and deep learning that have shown compelling potential for this purpose. P2-bMRI reuses the imaging data of examinations performed in the current practice. Accordingly, P2-bMRI could optimise clinical workflow, enabling cost savings and ultimately improving personalisation of treatment. This review introduces the concept of P2-bMRI, focusing on the clinical application of P2-bMRI by using semantic criteria.

Radiogenomics analysis reveals the associations of dynamic contrast-enhanced-MRI features with gene expression characteristics, PAM50 subtypes, and prognosis of breast cancer

BACKGROUND

To investigate reliable associations between dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) features and gene expression characteristics in breast cancer (BC) and to develop and validate classifiers for predicting PAM50 subtypes and prognosis from DCE-MRI non-invasively.

METHODS

Two radiogenomics cohorts with paired DCE-MRI and RNA-sequencing (RNA-seq) data were collected from local and public databases and divided into discovery (n = 174) and validation cohorts (n = 72). Six external datasets (n = 1,443) were used for prognostic validation. Spatial-temporal features of DCE-MRI were extracted, normalized properly, and associated with gene expression to identify the imaging features that can indicate subtypes and prognosis.

RESULTS

Expression of genes including RBP4, MYBL2, and LINC00993 correlated significantly with DCE-MRI features (q-value < 0.05). Importantly, genes in the cell cycle pathway exhibited a significant association with imaging features (p-value < 0.001). With eight imaging-associated genes (CHEK1, TTK, CDC45, BUB1B, PLK1, E2F1, CDC20, and CDC25A), we developed a radiogenomics prognostic signature that can distinguish BC outcomes in multiple datasets well. High expression of the signature indicated a poor prognosis (p-values < 0.01). Based on DCE-MRI features, we established classifiers to predict BC clinical receptors, PAM50 subtypes, and prognostic gene sets. The imaging-based machine learning classifiers performed well in the independent dataset (areas under the receiver operating characteristic curve (AUCs) of 0.8361, 0.809, 0.7742, and 0.7277 for estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2)-enriched, basal-like, and obtained radiogenomics signature). Furthermore, we developed a prognostic model directly using DCE-MRI features (p-value < 0.0001).

CONCLUSIONS

Our results identified the DCE-MRI features that are robust and associated with the gene expression in BC and displayed the possibility of using the features to predict clinical receptors and PAM50 subtypes and to indicate BC prognosis.

Breast Tumor Identification in Ultrafast MRI Using Temporal and Spatial Information

Simple Summary

The diagnosis of breast cancer with MRI is based on both morphological evaluation and kinetic curve assessment. Current computer-aided diagnosis methods for malignancy determination mainly focus on morphology features but ignored the temporal information in dynamic contrast-enhanced MRI sequences. Malignant and benign lesions usually have different enhancement patterns during the wash-in phase. Ultrafast breast MRI with high temporal resolution can capture the inflow of contrast in breast lesions. This advantage of ultrafast MRI enables the combination of both temporal and spatial information for automatic breast lesion analysis model development. We found that temporal information helps to significantly improve the performance of breast lesion classification. This suggests that ultrafast MRI provides useful information for malignancy identification and temporal information, which is indispensable for similar model development.

Abstract

Purpose: To investigate the feasibility of using deep learning methods to differentiate benign from malignant breast lesions in ultrafast MRI with both temporal and spatial information. Methods: A total of 173 single breasts of 122 women (151 examinations) with lesions above 5 mm were retrospectively included. A total of 109 out of 173 lesions were benign. Maximum intensity projection (MIP) images were generated from each of the 14 contrast-enhanced T1-weighted acquisitions in the ultrafast MRI scan. A 2D convolutional neural network (CNN) and a long short-term memory (LSTM) network were employed to extract morphological and temporal features, respectively. The 2D CNN model was trained with the MIPs from the last four acquisitions to ensure the visibility of the lesions, while the LSTM model took MIPs of an entire scan as input. The performance of each model and their combination were evaluated with 100-times repeated stratified four-fold cross-validation. Those models were then compared with models developed with standard DCE-MRI which followed the same data split. Results: In the differentiation between benign and malignant lesions, the ultrafast MRI-based 2D CNN achieved a mean AUC of 0.81 ± 0.06, and the LSTM network achieved a mean AUC of 0.78 ± 0.07; their combination showed a mean AUC of 0.83 ± 0.06 in the cross-validation. The mean AUC values were significantly higher for ultrafast MRI-based models than standard DCE-MRI-based models. Conclusion: Deep learning models developed with ultrafast breast MRI achieved higher performances than standard DCE-MRI for malignancy discrimination. The improved AUC values of the combined models indicate an added value of temporal information extracted by the LSTM model in breast lesion characterization.

Breast Cancer Classification on Multiparametric MRI - Increased Performance of Boosting Ensemble Methods

Introduction: This study aims to assess the utility of Boosting ensemble classification methods for increasing the diagnostic performance of multiparametric Magnetic Resonance Imaging (mpMRI) radiomic models, in differentiating benign and malignant breast lesions. Methods: The dataset includes mpMR images of 140 female patients with mass-like breast lesions (70 benign and 70 malignant), consisting of Dynamic Contrast Enhanced (DCE) and T2-weighted sequences, and the Apparent Diffusion Coefficient (ADC) calculated from the Diffusion Weighted Imaging (DWI) sequence. Tumor masks were manually defined in all consecutive slices of the respective MRI volumes and 3D radiomic features were extracted with the Pyradiomics package. Feature dimensionality reduction was based on statistical tests and the Boruta wrapper. Hierarchical Clustering on Spearman's rank correlation coefficients between features and Random Forest classification for obtaining feature importance, were implemented for selecting the final feature subset. Adaptive Boosting (AdaBoost), Gradient Boosting (GB), Extreme Gradient Boosting (XGBoost) and Light Gradient Boosting Machine (LightGBM) classifiers, were trained and tested with bootstrap validation in differentiating breast lesions. A Support Vector Machine (SVM) classifier was also exploited for comparison. The Receiver Operator Characteristic (ROC) curves and DeLong's test were utilized to evaluate the classification performances. Results: The final feature subset consisted of 5 features derived from the lesion shape and the first order histogram of DCE and ADC images volumes. XGboost and LGBM achieved statistically significantly higher average classification performances [AUC = 0.95 and 0.94 respectively], followed by Adaboost [AUC = 0.90], GB [AUC = 0.89] and SVM [AUC = 0.88]. Conclusion: Overall, the integration of Ensemble Learning methods within mpMRI radiomic analysis can improve the performance of computer-assisted diagnosis of breast cancer lesions.

Radiomics in breast MRI: current progress toward clinical application in the era of artificial intelligence

Breast magnetic resonance imaging (MRI) is the most sensitive imaging modality for breast cancer diagnosis and is widely used clinically. Dynamic contrast-enhanced MRI is the basis for breast MRI, but ultrafast images, T2-weighted images, and diffusion-weighted images are also taken to improve the characteristics of the lesion. Such multiparametric MRI with numerous morphological and functional data poses new challenges to radiologists, and thus, new tools for reliable, reproducible, and high-volume quantitative assessments are warranted. In this context, radiomics, which is an emerging field of research involving the conversion of digital medical images into mineable data for clinical decision-making and outcome prediction, has been gaining ground in oncology. Recent development in artificial intelligence has promoted radiomics studies in various fields including breast cancer treatment and numerous studies have been conducted. However, radiomics has shown a translational gap in clinical practice, and many issues remain to be solved. In this review, we will outline the steps of radiomics workflow and investigate clinical application of radiomics focusing on breast MRI based on published literature, as well as current discussion about limitations and challenges in radiomics.

AI-enhanced breast imaging: Where are we and where are we heading?

Significant advances in imaging analysis and the development of high-throughput methods that can extract and correlate multiple imaging parameters with different clinical outcomes have led to a new direction in medical research. Radiomics and artificial intelligence (AI) studies are rapidly evolving and have many potential applications in breast imaging, such as breast cancer risk prediction, lesion detection and classification, radiogenomics, and prediction of treatment response and clinical outcomes. AI has been applied to different breast imaging modalities, including mammography, ultrasound, and magnetic resonance imaging, in different clinical scenarios. The application of AI tools in breast imaging has an unprecedented opportunity to better derive clinical value from imaging data and reshape the way we care for our patients. The aim of this study is to review the current knowledge and future applications of AI-enhanced breast imaging in clinical practice.

Radiomics and deep learning methods in expanding the use of screening breast MRI

KEY POINTS

• The use of screening breast MRI is expanding beyond high-risk women to include intermediate- and average-risk women.• The study by Pötsch et al uses a radiomics-based method to decrease the number of benign biopsies while maintaining high sensitivity.• Future studies will likely increasingly focus on deep learning methods and abbreviated MRI data.